Aclaris Therapeutics Stock Price, News & Analysis (NASDAQ:ACRS)

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ACRS shares.
View ACRS analyst ratings or view top-rated stocks.

8 equities research analysts have issued 12-month price objectives for Aclaris Therapeutics' shares. Their ACRS share price targets range from $9.00 to $38.00. On average, they predict the company's share price to reach $23.17 in the next twelve months. This suggests a possible upside of 2,501.8% from the stock's current price.
View analysts price targets for ACRS or view top-rated stocks among Wall Street analysts.

Aclaris Therapeutics' stock was trading at $15.75 on January 1st, 2023. Since then, ACRS shares have decreased by 94.3% and is now trading at $0.8904.
View the best growth stocks for 2023 here.

Aclaris Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 7,390,000 shares, an increase of 12.3% from the October 31st total of 6,580,000 shares. Based on an average trading volume of 3,720,000 shares, the days-to-cover ratio is presently 2.0 days.
View Aclaris Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our ACRS earnings forecast.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) posted its quarterly earnings results on Monday, November, 6th. The biotechnology company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.07. The biotechnology company had revenue of $9.30 million for the quarter, compared to analysts' expectations of $1.57 million. Aclaris Therapeutics had a negative net margin of 534.83% and a negative trailing twelve-month return on equity of 64.53%. The company's revenue for the quarter was down 51.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.30) EPS.

ETFs with the largest weight of Aclaris Therapeutics (NASDAQ:ACRS) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Trevena (TRVN), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Abeona Therapeutics (ABEO) and Aldeyra Therapeutics (ALDX).

Aclaris Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Blackstone Inc. (1.78%), Assenagon Asset Management S.A. (0.97%), FMR LLC (0.93%), Charles Schwab Investment Management Inc. (0.65%), Lord Abbett & CO. LLC (0.64%) and HighTower Advisors LLC (0.52%). Insiders that own company stock include Andrew N Schiff, David N Gordon, Douglas J Manion, Frank Ruffo, James Loerop, Joseph Monahan, Kamil Ali-Jackson, Kevin Balthaser and Neal Walker.
View institutional ownership trends.

Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.